[Asia Economy Reporter Jang Hyowon] Canaria Bio Group's holding company, Canaria Bio M, announced on the 16th that it has signed a 'share transfer agreement involving a change of major shareholder' to acquire management rights of Leaders Technology Investment from AT Semicon for 25 billion KRW.
Over the past year, Canaria Bio Group has expanded its group companies by acquiring four companies: Hyundai Feed, Sejong Medical, Doowon Science Pharma, and Helixmith. By acquiring Leaders Technology Investment, a new technology business financial company (Shingisa), the group explained that it has now laid the foundation to focus not only on strategic M&A but also on financial M&A for investors as its main business. Canaria Bio Group plans to instill its accumulated capital raising network and deal sourcing capabilities into Leaders Technology Investment to develop it into a representative M&A specialized investment company.
A representative of Canaria Bio Group stated, “Our goal is to grow the company into one that makes focused investments with a long-term perspective, like Warren Buffett's Berkshire Hathaway,” adding, “The difference from Warren Buffett's investment philosophy is that we invest in new technologies such as bio.”
He continued, “If the co-sale rights allowing minority shareholders to enjoy a 'management premium' are legislated, the M&A market will be shaken. We are considering various strategic directions to respond to the rapidly changing market situation in solidarity with minority shareholders,” and added, “As part of this, we will attempt to enable access through crowdfunding methods that gather funds from a large public via online platforms by revitalizing public offering associations, rather than private M&A funds that were difficult for small investors to approach.”
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.

